Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo

详细信息    查看全文

• 作者：Tong Wu^a ; ^b ; Zhen Chen^b ; Kenneth K.W. To^c ; Xiaona Fang^b ; Fang Wang^b ; Bin Cheng^a ; ¹ ; ^{chengbin@mail.sysu.edu.cn} ; Liwu Fu^b ; ¹ ; ^{Fulw@mail.sysu.edu.cn}
• 关键词：MDR ; multidrug resistance ; DOX ; doxorubicin ; Rho 123 ; rhodamine 123 ; ABC ; adenosine triphosphate (ATP)-binding cassette ; ABCB1 ; ABC transporter subfamily B member 1 ; ABCG2 ; ABC transporter subfamily G member 2 ; CDK ; cyclin D-cyclin dependent kinase ; Rb ; retinoblastoma ; VRP ; verapamil ; FTC ; fumitremorgin C ; MTT ; 3-(4 ; 5-dimethylthiazol-2yl)-2 ; 5-diphenyltetrazoliumbromide ; DMEM ; Dulbecco&rsquo ; s modified Eagle&rsquo ; s medium ; DMSO ; dimethyl sulfoxide ; PCR ; polymerase chain reaction ; IAAP ; iodoaryla
• 刊名：Biochemical Pharmacology
• 出版年：2017
• 出版时间：15 January 2017
• 年：2017
• 卷：124
• 期：Complete
• 页码：29-42
• 全文大小：4592 K
• 卷排序：124

文摘

Multidrug resistance (MDR) is the major obstacle of the success in cancer chemotherapy. The overexpression of ATP-binding cassette (ABC) transporters, particularly ABCB1 and ABCG2, play a significant role in mediating MDR by pumping anticancer drugs out of cancer cells. Abemaciclib (LY2835219) is an orally bioavailable CDK4/6 inhibitor under phase III clinical trials. Here, we found that LY2835219 remarkably enhanced the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 over-expressing cancer cells in vitro and in vivo. Furthermore, LY2835219 significantly increased the intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells. Mechanistically, LY2835219 is likely a competitive inhibitor of ABCB1 and ABCG2 for its competition with [125I]-iodoarylazidoprazosin for photo affinity labeling of the transporters. On the other hand, at the transporters-inhibiting concentrations, LY2835219 did not alter the expression level of ABCB1 and ABCG2, and the phosphorylation status of retinoblastoma (Rb) pathway in both parental and their resistant cells. In conclusion, these findings revealed a novel role of LY2835219 in reversing ABCB1 or ABCG2-mediated MDR, which may be benefit to the patients with MDR cancer for combinational therapy.